Supply / Manufacturing · GCC · Announced 28 Jan 2026
Chemo & Olpha → CCL Pharmaceuticals
Pakistan's CCL has signed agreements with Chemo and Olpha to bring CCL-branded medicines made at US FDA- and EU-GMP-certified sites to Saudi Arabia, the UAE, Qatar, Oman and Bahrain — using European manufacturing as its route into the Gulf.
Parties: Chemo & Olpha (Spain / Latvia) → CCL Pharmaceuticals (Pakistan)
- Deal type
- Supply / Manufacturing
- Value
- Undisclosed
- Territory
- Saudi Arabia, UAE, Qatar, Oman, Bahrain
- Therapeutic area
- Multi-therapy
- Asset
- CCL-branded medicines made at US FDA- and EU-GMP-certified facilities (products not named)
- Announced
- 28 Jan 2026
Our analysis
Why this matters
CCL Pharmaceuticals & Life Sciences, the international face of one of Pakistan's leading drugmakers, has signed strategic agreements with two European manufacturers, Chemo and Olpha, to introduce its brands in Saudi Arabia, the UAE, Qatar, Oman and Bahrain. Under the partnerships, CCL will commercialise CCL-branded products manufactured at US FDA- and EU-GMP-certified facilities, according to the company's announcement.
The structure is the story. Rather than exporting from its plants in Pakistan and Vietnam, CCL is putting its brand on European-made product. In the GCC, where regulators and hospital tender committees weigh manufacturing-site credentials heavily, EU-GMP and FDA-inspected sites are a far easier sell than a first-time South Asian exporter. CCL keeps the brand, the portfolio choices and the commercial relationship; its partners carry the regulatory weight of the factory.
The full analysis is free to read with a work email on this page.
Source: Gulf News (Reach partner content, company announcement)